Schedule Dispatches

November 2026 | New Listings

• Cetirizine hydrochloride (Noumed Cetirizine Hayfever & Allergy Relief) oral liq 1 mg per ml, 200 ml (p’code 2739933)
• Fluconazole (APO Fluconazole) cap 200 mg – s29 and wastage claimable (p’code 2735024)
• Naltrexone hydrochloride (Naltrexone Lupin) tab 50 mg – Special Authority – Retail pharmacy (p’code 2733307)
• Pioglitazone (Rising) tab 15 mg (p’code 2739917) and tab 30 mg (p’code 2739925) – s29 and wastage claimable
• Taurine (Solgar) cap 500 mg – Special Authority – Retail pharmacy (p’code 2563193)

Changes to restrictions, chemical names and presentations

• Abacavir sulphate (Ziagen) tab 300 mg – removal of Special Authority criteria
• Abacavir sulphate with lamivudine (Abacavir/Lamivudine Viatris) tab 600 mg with lamivudine 300 mg – removal of Special Authority criteria
• Adalimumab (Amgevita) inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled pen and inj 40 mg per 0.8 ml prefilled syringe – amended Special Authority criteria
• Adalimumab (Humira - Alternative Brand) inj 20 mg per 0.2 ml prefilled syringe and inj 40 mg per 0.4 ml prefilled syringe (Humira) and inj 40 mg per 0.4 ml prefilled pen (HumiraPen) – amended Special Authority criteria
• Antiretrovirals – addition of note and removal of Special Authority criteria
• Atazanavir sulphate (Atazanavir Viatris) cap 150 mg and 200 mg – removal of Special Authority criteria
• Bedaquiline (Sirturo) tab 100 mg, 24 OP – amended Special Authority criteria
• Blood ketone diagnostic test strip (KetoSens) test strips, 10 strip OP – amended subsidy by endorsement
• Captopril (DP-Captopril) oral liq 5 mg per ml, 100 ml OP – amended note
• Darunavir (Darunavir Viatris) tab 400 mg and 600 mg – removal of Special Authority criteria
• Dolutegravir (Tivicay) tab 50 mg – addition of subsidy by endorsement, PSO and note and removal of Special Authority criteria
• Dolutegravir with lamivudine (Dovato) tab 50 mg with lamivudine 300 mg – removal of Special Authority criteria
• Efavirenz with emtricitabine and tenofovir disoproxil tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) (TEEVIR, TEEVIR (India), Tenofovir Efavirenz Emtricitabine (Mylan)) and tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) (Viatris) – removal of Special Authority criteria and note
• Emtricitabine (Emtriva) cap 200 mg – removal of Special Authority criteria
• Emtricitabine with tenofovir disoproxil tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate) (Tenofovir Disoproxil Emtricitabine Mylan) and tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) (Tenofovir Disoproxil Emtricitabine Viatr) – amended subsidy by endorsement, removal of Special Authority criteria and addition of PSO and note
• Etravirine (Intelence) tab 200 mg – removal of Special Authority criteria
• Fluconazole (Diflucan) powder for oral suspension 10 mg per ml, 35 ml – amended Special Authority criteria
• Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] (Gardasil 9) inj 270 mcg in 0.5 ml syringe – amended eligibility criteria
• Ibrutinib (Imbruvica) tab 140 mg and tab 420 mg – amended Special Authority criteria
• Ipilimumab inj 5 mg per ml, 10 ml vial and inj 5 mg per ml, 40 ml vial (Yervoy) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Itraconazole (Itraconazole Kent) oral liq 10 mg per ml, 150 ml OP – amended Special Authority criteria
• Lamivudine tab 150 mg (Lamivudine Viatris) and oral liq 10 mg per ml, 240 ml OP (3TC) – removal of Special Authority criteria
• Linezolid (Zyvox) tab 600 mg and oral liq 20 mg per ml, 150 ml – amended Special Authority criteria
• Lopinavir with ritonavir (Lopinavir/Ritonavir Mylan) tab 200 mg with ritonavir 50 mg – removal of Special Authority criteria
• Nevirapine tab 200 mg (Nevirapine Viatris) and oral suspension 10 mg per ml, 240 ml OP (Viramune Suspension) – removal of Special Authority criteria
• Nivolumab inj 10 mg per ml, 4 ml vial and inj 10 mg per ml, 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Raltegravir potassium tab 400 mg (Isentress) and tab 600 mg (Isentress HD) – removal of Special Authority criteria
• Ritonavir (Norvir) tab 100 mg – removal of Special Authority criteria
• Tamsulosin hydrochloride (Tamsulosin-Rex) cap 400 mcg – reinstate stat dispensing
• Tenofovir disoproxil tab 245 mg (300 mg as a maleate) (Tenofovir Disoproxil Viatris) and tab 245 mg (300 mg as a fumarate) (Ricovir) – removal of note
• Teriparatide (Teriparatide Teva) inj 250 mcg per ml, 2.4 ml – amended brand name and removal of s29
• Venetoclax (Venclexta) – amended Special Authority criteria
• Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, 42 OP
• Tab 10 mg, 2 OP
• Tab 50 mg, 7 OP
• Tab 100 mg
• Zidovudine (Retrovir) cap 100 mg and oral liq 10 mg per ml, 200 ml OP – removal of Special Authority criteria
• Zidovudine with lamivudine (Lamivudine/Zidovudine Viatris) tab 300 mg with lamivudine 150 mg – removal of Special Authority criteria

Increased Subsidy

Chemical	Presentation	Fully subsidised brands
Aspirin	Tab dispersible 300 mg	Ethics Aspirin
Methotrexate	Inj 100 mg per ml, 50 ml vial	Methotrexate Ebewe
	Inj 1 mg for ECP	Baxter
Morphine hydrochloride	Oral liq 2 mg per ml, 200 ml Oral liq 5 mg per ml, 200 ml	RA-Morph

Decreased Subsidy

Chemical	Presentation	Fully subsidised brands
Imatinib mesilate	Cap 100 mg and 400 mg	Imatinib-Rex

Changes to General Rules

We have made amendments to Pharmaceutical Schedule Rules to give effect to the Paediatric Oncology Funding Policy from 1 November 2026.